PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has revealed significant progress in its pipeline and operations, underscoring its focus on advancing rese-cel, a cell therapy candidate for ...

This collaboration will extend to all aspects of cell therapy manufacturing including Chemistry, Manufacturing and Controls (CMC), Quality Assurance and Quality Control. As part of this ...

Barinthus Biotherapeutics plc has announced its strategic transformation focusing ... VTP-1000 has promise to be a leading therapy for the approximate 80 million people worldwide with celiac ...